Paget's disease

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Risk, Woman, Hypercalcaemia, Menopause, Man, Cancer, Avascular necrosis, Risk management, Anatomy, Female, IIA, Osteitis, Jaw, Osteoclast, CHMP, Fever, Fracture, ATC, Pain, European, Disease, Calcium, Kidney, Paget's disease, Glucocorticoid, Neoplasm, Arthralgia, Hypocalcemia, Patient, Medical Subject Headings, Hip, Trauma, European Commission, Vitamin D, International, Language, Mouth, Select, Medicine, Paget's disease of bone, Allergy, Headache, Ibuprofen, Spine, Myalgia, Committee, Cell, Necrosis, Dietary supplement

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Retrieved on: 
Thursday, March 16, 2023
Shanda, Cancer, Radiation, New Drug Application, TLX, Dysplasia, Nausea, PET, Lymph, Serum, Risk, Diarrhea, Novartis, Prostate cancer, Osteophyte, CT, PSMA, Patient, Judgement, Paget, PSA, Gallium, Dizziness, FDA, Paget's disease, Disease, Safety, ASX, Pharmaceutical industry, Medical imaging, Telix, Gallium (68Ga) gozetotide

Kevin Richardson, Chief Executive Officer for Telix Americas said, "We welcome the FDA's decision to expand the label indication for Illuccix.

Key Points: 
  • Kevin Richardson, Chief Executive Officer for Telix Americas said, "We welcome the FDA's decision to expand the label indication for Illuccix.
  • This additional indication further demonstrates our continued commitment to support patients fighting prostate cancer and to empower the doctors who treat them.
  • Use of Illuccix in the VISION Phase III study (ClinicalTrials.gov Identifier: NCT03511664 )[4] helped doctors detect prostate cancer and identify the appropriate patients for PSMA-based radioligand therapy.
  • There's no doubt that appropriate selection of patients for PSMA targeted radioligand therapy is dependent on appropriate imaging.

Global Bone Cancer Diagnosis and Therapeutics Market Report 2022: R&D and Technological Advancements & New Product Launches to Bolster Growth - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Biotechnology, Health, Oncology, Medical Devices, News, Paget's disease, Bayer, Novartis, R, Therapy, Multiple myeloma, Diagnosis, Health, Ewing's sarcoma, Amgen, Denosumab, Growth, Patient, Transplant, Cancer, BeiGene, Pfizer, Merck & Co., Bone metastasis, Chondrosarcoma, Acquisition, Bone, Medical device, Agriculture, Pharmaceutical industry, Medical imaging, Marketing, Osteosarcoma

The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • However, lack of awareness in under developed nations with regards to diagnosis and therapeutics along with high cost involvement in treatment are some major factors constraints that are hindering the growth of the global bone cancer diagnosis and therapeutics market.
  • New product launches in the market are likely to drive the growth of the global bone cancer diagnosis and therapeutics market.
  • Key players of the global bone cancer diagnosis and therapeutics market are Amgen Inc., Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others.

Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network

Retrieved on: 
Monday, June 13, 2022
Australian Securities Exchange, Gallium, Dysplasia, PET, Paget, Company, PSMA, Pharmacy, PSA, Man, Nausea, MTR, Food, LinkedIn, TGA, TLX, Paget's disease, Dizziness, Prostate cancer, Physician, Chief executive officer, Serum, FDA, Patient, Cancer, Risk, Antiandrogen, Radiation, Diarrhea, Control, ADT, Degenerative disease, Plasma protein binding, Disclosure, ASX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymph, Safety, Osteophyte, Medical imaging, Pharmaceutical industry, Animal, Telix

Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.

Key Points: 
  • Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.
  • The expansion of the distribution network facilitates broader patient access to Illuccix across the country, expanding availability into new regional markets that to date have had limited access to PSMA PET imaging.
  • Our goal is to ensure broad access to PSMA PET imaging from the largest metropolitan cities to regional areas and the expansion of the distribution network to include Jubilant Radiopharma puts an Illuccix scan within reach of even more patients in need."
  • "We are pleased to be able to expand our range and service to include Illuccix, and offer our customers the added convenience of PSMA PET imaging with Illuccix," says Renato Leite, President, Jubilant Radiopharmacies Division.

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

Retrieved on: 
Friday, June 10, 2022
Australian Securities Exchange, Gallium, Radiation, Dysplasia, Caregiver, PET, Paget, SRS, PSMA, Lymph, PSA, Man, Company, Nausea, MTR, Toxicity, Food, LinkedIn, TGA, Partnership, Cancer, Positron, TLX, IMRT, Paget's disease, Prostate cancer, Dizziness, Osteophyte, Serum, FDA, Patient, Hospital, Risk, Technology, Antiandrogen, Twitter, Diarrhea, Reflection, ADT, Degenerative disease, Plasma protein binding, ASX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Safety, SBRT, Medical imaging, Pharmaceutical industry, Telix, Control

RefleXion is exclusively partnering with Telix for 68Ga PSMA-PET imaging agents for use with BgRT.

Key Points: 
  • RefleXion is exclusively partnering with Telix for 68Ga PSMA-PET imaging agents for use with BgRT.
  • More than 60,000 men undergo external-beam radiotherapy for prostate cancer every year in the U.S. alone[2].
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.You may also report adverse reactions to Telix by calling1-844-455-8638or via email to [email protected] .

Global Musculoskeletal Partnering Deal Trends, Players and Financials Analysis Report 2021: Analyse Deals Entered into by the World's Leading Life Science Companies Since 2014 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 20, 2022
Health, Hospitals, Research, Technology, Back pain, Psoriatic arthritis, Hip, Paget's disease, Ankylosing spondylitis, Bone fracture, Stiffness, Gout, Rheumatoid arthritis, Knee, Finance, Weakness, Muscular dystrophy, Osteoarthritis, Musculoskeletal disorder, Players, Bone pain, Myalgia, Contract, Arthritis, Childhood arthritis, Veterinary medicine, Osteoporosis, Human musculoskeletal system

The "Global Musculoskeletal Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Musculoskeletal Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Musculoskeletal Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals.
  • The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.
  • The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2014.